JP5735551B2 - Ｃ型肝炎の処置のための化合物 - Google Patents

Ｃ型肝炎の処置のための化合物 Download PDF

Info

Publication number
JP5735551B2
JP5735551B2 JP2012557233A JP2012557233A JP5735551B2 JP 5735551 B2 JP5735551 B2 JP 5735551B2 JP 2012557233 A JP2012557233 A JP 2012557233A JP 2012557233 A JP2012557233 A JP 2012557233A JP 5735551 B2 JP5735551 B2 JP 5735551B2
Authority
JP
Japan
Prior art keywords
fluoro
fluorophenyl
carboxamide
methyl
hplc grade
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2012557233A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013522224A (ja
JP2013522224A5 (enExample
Inventor
カップ−サン・ユン
キャサリン・エイ・グラント−ヤング
ジョン・エフ・カドウ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of JP2013522224A publication Critical patent/JP2013522224A/ja
Publication of JP2013522224A5 publication Critical patent/JP2013522224A5/ja
Application granted granted Critical
Publication of JP5735551B2 publication Critical patent/JP5735551B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2012557233A 2010-03-11 2011-03-10 Ｃ型肝炎の処置のための化合物 Expired - Fee Related JP5735551B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US31276810P 2010-03-11 2010-03-11
US61/312,768 2010-03-11
US13/043,747 US8354410B2 (en) 2010-03-11 2011-03-09 Compounds for the treatment of hepatitis C
US13/043,747 2011-03-09
PCT/US2011/027823 WO2011112769A1 (en) 2010-03-11 2011-03-10 Compounds for the treatment of hepatitis c

Publications (3)

Publication Number Publication Date
JP2013522224A JP2013522224A (ja) 2013-06-13
JP2013522224A5 JP2013522224A5 (enExample) 2014-05-01
JP5735551B2 true JP5735551B2 (ja) 2015-06-17

Family

ID=43903118

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012557233A Expired - Fee Related JP5735551B2 (ja) 2010-03-11 2011-03-10 Ｃ型肝炎の処置のための化合物

Country Status (8)

Country Link
US (1) US8354410B2 (enExample)
EP (1) EP2545051B1 (enExample)
JP (1) JP5735551B2 (enExample)
KR (1) KR20130016263A (enExample)
CN (1) CN102892767A (enExample)
AU (1) AU2011224319A1 (enExample)
MX (1) MX2012010216A (enExample)
WO (1) WO2011112769A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130302282A1 (en) 2010-10-26 2013-11-14 Presidio Pharmaceuticals, Inc. Inhibitors of Hepatitis C Virus
US8507683B2 (en) * 2010-12-09 2013-08-13 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US9303020B2 (en) 2012-02-08 2016-04-05 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US9434738B2 (en) 2013-01-10 2016-09-06 Bristol-Myers Squibb Company Macrocyclic benzofuran and azabenzofuran compounds for the treatment of hepatitis C
EP2961746B1 (en) 2013-02-28 2018-01-03 Bristol-Myers Squibb Company Phenylpyrazole derivatives as potent rock1 and rock2 inhibitors
TW201444798A (zh) 2013-02-28 2014-12-01 必治妥美雅史谷比公司 作爲強效ｒｏｃｋ１及ｒｏｃｋ２抑制劑之苯基吡唑衍生物
WO2014205594A1 (en) * 2013-06-24 2014-12-31 Merck Sharp & Dohme Corp. Substituted benzofuran compounds and methods of use thereof for treatment of viral diseases
WO2014205592A1 (en) * 2013-06-24 2014-12-31 Merck Sharp & Dohme Corp. Heterocyclic compounds and methods of use thereof for treatment of hepatitis c
WO2015143256A1 (en) * 2014-03-21 2015-09-24 Bristol-Myers Squibb Company Cyanoamino (aza)benzofuran compounds for the treatment of hepatitis c
CN105732602B (zh) * 2015-09-23 2017-04-19 常州寅盛药业有限公司 作为ns4b抑制剂的苯并呋喃类似物
CN114957110A (zh) * 2021-02-26 2022-08-30 清华大学 一种抗病毒化合物及其制备方法和应用
WO2023208171A1 (zh) * 2022-04-29 2023-11-02 清华大学 PLpro蛋白抑制剂及其制备方法和应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57123181A (en) 1981-01-23 1982-07-31 Mitsubishi Paper Mills Ltd Preparation of pyrazolo (1,5-a) pyridine derivative
EP1140901A2 (en) * 1998-12-24 2001-10-10 Aventis Pharmaceuticals Products Inc. Substituted (aminoiminomethyl or aminomethyl)benzoheteroaryl compounds as factor xa inhibitors
PE20020506A1 (es) 2000-08-22 2002-07-09 Glaxo Group Ltd Derivados de pirazol fusionados como inhibidores de la proteina cinasa
WO2002078701A1 (en) 2001-03-30 2002-10-10 Smithkline Beecham Corporation Use of pyrazolopyridines as therapeutic compounds
BR0315937A (pt) 2002-11-01 2005-09-13 Viropharma Inc Composto, composição para a profilaxia ou tratamento de infecções virais, e, método para a profilaxia ou tratamento de infecções da hepatite c e doenças associadas com tais infecções em um hospedeiro vivo
US7868037B2 (en) 2004-07-14 2011-01-11 Ptc Therapeutics, Inc. Methods for treating hepatitis C
MX2009008439A (es) * 2007-02-12 2009-08-13 Intermune Inc Nuevos inhibidores de la replicacion del virus de hepatitis c.
GB0707000D0 (en) 2007-04-12 2007-05-30 Istituto Di Ricerche D Biolog Antiviral agents
CA2714254A1 (en) 2008-02-14 2009-08-20 F. Hoffmann-La Roche Ag Heterocyclic antiviral compounds
WO2009137500A1 (en) 2008-05-05 2009-11-12 Wyeth 6-substituted benzofuran compounds to treat infection with hepatitis c virus
WO2009137493A1 (en) 2008-05-05 2009-11-12 Wyeth 2-substituted benzofuran compounds to treat infection with hepatitis c virus
US8198449B2 (en) 2008-09-11 2012-06-12 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7994171B2 (en) * 2008-09-11 2011-08-09 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US8048887B2 (en) * 2008-09-11 2011-11-01 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
WO2011103063A1 (en) 2010-02-19 2011-08-25 Glaxo Group Limited Therapeutic compounds
GB2482102B (en) 2010-03-01 2012-09-12 Plascoenergy Ip Holdings S L Bilbao Schaffhausen Branch A lateral transfer system
TW201136919A (en) 2010-03-02 2011-11-01 Merck Sharp & Amp Dohme Corp Inhibitors of hepatitis C virus NS5B polymerase
WO2011106929A1 (en) 2010-03-02 2011-09-09 Merck Sharp & Dohme Corp. Inhibitors of hepatitis c virus ns5b polymerase

Also Published As

Publication number Publication date
CN102892767A (zh) 2013-01-23
KR20130016263A (ko) 2013-02-14
AU2011224319A1 (en) 2012-11-01
JP2013522224A (ja) 2013-06-13
US20120059019A1 (en) 2012-03-08
MX2012010216A (es) 2012-10-03
WO2011112769A1 (en) 2011-09-15
EP2545051B1 (en) 2017-04-19
EP2545051A1 (en) 2013-01-16
US8354410B2 (en) 2013-01-15

Similar Documents

Publication Publication Date Title
JP5735551B2 (ja) Ｃ型肝炎の処置のための化合物
EP2545050B1 (en) Compounds for the treatment of hepatitis c
JP5343011B2 (ja) Ｃ型肝炎の治療のための化合物
US7998951B2 (en) HCV NS5B inhibitors
WO2007143521A1 (en) Cyclopropyl fused indolobenzazepine hcv inhibitors
KR20110056537A (ko) Ｃ형 간염의 치료를 위한 화합물
JP2012519173A (ja) シクロプロピル縮合インドロベンズアゼピンｈｃｖｎｓ５ｂ阻害剤
EP2588464B1 (en) Benzofuran derivatives for the treatment of hepatits c
EP2276764B1 (en) Compounds for the treatment of hepatitis c
JP2018509401A (ja) Ｃ型肝炎の治療のための新規化合物
JP2013520507A (ja) Ｃ型肝炎の処置のためのピラゾロピリダジン誘導体
JP2016505011A (ja) Ｃ型肝炎の治療用の大環状ベンゾフランおよびアザベンゾフラン化合物
JP2011515484A (ja) ピロリジン縮合インドロベンザジアゼピンｈｃｖｎｓ５ｂ阻害剤
CN101980711B (zh) 芳族杂环稠合的吲哚并苯并二氮杂*hcv ns5b抑制剂
US20130102589A1 (en) Novel Compound for the Treatment of Hepatitis C
JP2017509700A (ja) Ｃ型肝炎治療用の含シアノアザベンゾフラン化合物
CN101981038B (zh) 二氧戊环和二氧戊环酮稠合的吲哚并苯并二氮杂*hcv ns5b抑制剂
WO2016133970A1 (en) Benzofurans substituted with primary benzamide as hcv inhibitors

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140307

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140312

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20141216

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20141218

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150302

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150407

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150416

R150 Certificate of patent or registration of utility model

Ref document number: 5735551

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees